AlphAIalphai — Financial news for AI agents
BenzingaNOV 143 min read$TELA

These Analysts Cut Their Forecasts On TELA Bio After Q3 Earnings - TELA Bio (NASDAQ:TELA)

TELA Bio Inc ( NASDAQ:TELA ) reported mixed results for the third quarter on Thursday. The company posted quarterly losses of 19 cents per share which beat the analyst consensus estimate of losses of 20 cents per share.

Original reporting
Benzinga · Avi Kapoor
Published Nov 14, 2025, 4:42 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 14, 2025, 5:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
These Analysts Cut Their Forecasts On TELA Bio After Q3 Earnings - TELA Bio (NASDAQ:TELA) — source image
Source · www.benzinga.com
Decision brief

The 30-second read

$TELANeutralLow
01

Why it matters

The mixed earnings and forecast cuts suggest limited upside in the short term, with potential for volatility as investors digest the news.

02

Market read

The news is highly relevant for investors holding or considering TELA Bio shares, with sector implications for biotech stocks.

03

What to watch

Potential upcoming catalysts such as new product launches or regulatory approvals could offset negative forecast revisions.

Timing: short-term (within days to weeks)

Background

TELA Bio reported Q3 earnings with a slight beat on losses, but analysts have reduced their forecasts, indicating cautious outlooks.

Company-level read

Ticker impact

$TELANeutralMedium confidence
Context

The news pertains directly to TELA Bio's recent earnings report and analyst forecast adjustments.

Expected impact

Potential short-term stabilization with slight downward pressure due to forecast cuts; long-term outlook remains uncertain pending further earnings data.

Evidence & confidence

The mixed earnings and analyst downgrades create uncertainty. The neutral sentiment and modest forecast adjustments suggest limited immediate price movement, but investor sentiment could shift with upcoming catalysts.

Market effects

Sector

Potential cautious sentiment in the life sciences sector due to mixed earnings reports.

Regional

Limited regional impact; primarily US-focused sector and company-specific news.

Global

Low; the news is specific to a US-based biotech company.

Counterpoint

What could challenge this read

The slight earnings beat and cautious analyst outlook may present a buying opportunity if the company demonstrates resilience in upcoming quarters.

Key entities

  • Company
    TELA Bio Inc

    A biotechnology company focused on developing and commercializing innovative surgical products.

Read at source← All news

Related articles

AUG 10
$TELAMed

TELA Bio, Inc. (TELA): Results of Operations and Financial Condition

TELA Bio, Inc. (TELA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622768d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 TELA Bio Reports Second Quarter 2026 Financial Results MALVERN, PA, August 10, 2026 -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction

SEC EDGAR 8-K4 min
AUG 11
$DISMed

Disney, Comcast reach deal, lifting NFL Network blackout

Comcast and Disney reached an agreement to end the NFL Network blackout for Comcast Xfinity TV subscribers, resuming NFL Network and NFL RedZone in time for the 2026 season. The blackout began after their contract expired in late April. Disney owns 72% of ESPN, which took over NFL Media assets earlier this year. Terms were not disclosed.

740thefan.com3 min
AUG 11
$ABUSMed

Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?

Arbutus Biopharma (ABUS) received about $178 million from Moderna (MRNA) as its share of a $950 million noncontingent LNP patent settlement, with reimbursement of legal costs and an expected Q3 dividend tied to Genevant. ABUS reported Q1 2026 revenue of $179.1 million and net income of $169.7 million. Moderna reported Q2 2026 revenue of $145 million and a net loss of $782 million, plus FDA approval for mFLUSIVA.

insidermonkey.com6 min
AUG 11
$IONQMedAI 8/10

Pentagon may see one of quantum computing’s first practical winners

IonQ (IONQ) said DARPA awarded a $28 million contract modification under its It’s About Time program to support production development and 25 Evergreen-05 optical atomic clocks, with a $30 million option for 100 additional clocks. IonQ plans to invest $15 million to scale manufacturing. The company cites timing performance for GPS-denied defense uses.

yahoo.com6 min
AUG 11
$CCEYFMedAI 8/10

CanCambria Energy Provides Updated Contingent Resource Evaluation for Flagship Deep Gas Project, Attributable to Strong European Natural Gas Prices, Driving an Increased NPV10 of US$2.04 Billion

CanCambria Energy Corp. (TSXV: CCEC) reported an updated independent contingent resource evaluation for its 100% owned Kiskunhalas deep gas project in southern Hungary. Prepared by CHPE (effective June 30, 2026), it assumes $12.00/MMBtu TTF1 gas. Risked 2C Development Pending NPV10 rose 16% to US$2.04B from US$1.762B; 2C volumes are 571.9 Bcf and 59.6 MMbbl. First gas is targeted for mid-2027.

oilandgas360.com4 min